CPRX Catalyst Pharmaceuticals
- 16.570
- +0.700+4.41%
- 16.270
- -0.300-1.81%
Catalyst Pharmaceuticals News
Catalyst Pharmaceuticals | 8-K: Current report
Catalyst Pharmaceuticals | 10-Q: Quarterly report
Catalyst Pharmaceuticals | 8-K: Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Tierney David S
Catalyst Pharmaceuticals | DEF 14A: Definitive information statements
Catalyst Pharmaceuticals | ARS: Annual Report to Security Holders
Catalyst Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Elsbernd Brian
Catalyst Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Catalyst Pharmaceuticals | 8-K: Current report
Catalyst Pharmaceuticals | 8-K: Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Catalyst Pharmaceuticals | 10-K: Annual report
Catalyst Pharmaceuticals | 8-K: Current report
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Elsbernd Brian
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer INGENITO GARY
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Harper Molly
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Sundaram Preethi
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Miller Steve
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director O'Keeffe Charles B
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Tierney David S
Analysis
Price Target
No Data
